



Medicine Supply Notification

MSN/2024/001

Isosorbide mononitrate (Isotard® 40XL) 40mg modified-release (MR) tablets
Isosorbide mononitrate (Zemon® 40 XL) 40mg modified-release (MR) tablets
Isosorbide mononitrate (Nyzamac® SR) 40mg modified-release (MR) capsules

Tier 2 – medium impact*

Date of issue: 03/01/2024

Link: [Medicines Supply Tool](#)

Summary

- Zemon® 40 XL tablets are out of stock until early January 2024.
- Nyzamac® SR 40mg capsules are out of stock until late January 2024.
- Isotard® 40XL tablets are out of stock until early February 2024.
- From early January, Zemon® 40 XL can support a partial increase in demand.
- ISMO Retard® 40mg tablets remain available, however they cannot support an increase in demand.
- Isosorbide mononitrate MR 50mg and 60mg preparations remain available and can support increased demand, including;
 - Isotard 50XL and 60XL tablets
 - Tardisc XL 60 tablets
 - Chemydur 60XL tablets
- Isosorbide mononitrate immediate release tablets remain available, however, patients should not be changed to these without clinical review.

Actions Required

No new patients should be initiated on Zemon® 40 XL, Isotard® 40XL or Nyzamac® SR 40mg capsules until the supply issues have resolved.

Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should consider prescribing one of the following to make up a dose as close as possible to that taken by patient (see supporting information):

- an alternative 40mg MR presentation, if available
- a 50mg MR tablet if the 40mg MR preparation(s) are not available
- a 60mg MR tablet (which can also be halved to provide 30mg doses) if the 40mg MR preparation(s) are not available

When changing brand or dose of a modified-release nitrate preparation, prescribers and pharmacy teams should counsel patients on the change and possible adverse events they may experience, particularly in the first few days, the most important being hypotension, tachycardia, and worsening headaches. If they have concerns, patients should be advised to contact their doctor.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

In addition, prescribers should:

- consider previous nitrate preparations tried and allergies to excipients when selecting a product;
- titrate dose according to response and side effects; and
- not switch patients to an immediate release preparation without clinical review of risk of worsening angina.

Supporting information

Zemon® 40 XL, Isotard® 40XL and Nyzamac® SR are licensed for the prophylactic treatment of angina pectoris. They are administered once daily in the morning, up to a maximum dose of 120mg once daily (whole dose to be given together as a daily nitrate-free period is required to prevent the development of tolerance).

The 50mg and 60mg MR preparations are administered once daily in the morning, up to a maximum dose of 100mg and 120mg once daily, respectively.

Links to further information

[SmPC: Zemon® 40 XL](#)

[SmPC: Isotard® 40 mg XL Tablets](#)

[SmPC: Nyzamac® SR Capsules](#)

[SmPC: Isosorbide mononitrate MR 50mg preparations](#)

[SmPC: Isosorbide mononitrate MR 60mg preparations](#)

[BNF: Nitrates](#)

[CKS: Choice of nitrate](#)

Enquiries

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2024/001

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.